Anzeige
Mehr »
Montag, 10.08.2026 - Börsentäglich über 12.000 News
Breaking News: Wirklich beeindruckende Ergebnisse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
10.08.26 | 21:56
30,270 Euro
+0,40 % +0,120
Branche
Chemie
Aktienmarkt
Japan 225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
29,85030,45022:45
29,97030,27022:01

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:26Silence brings the noise to Takeda with phase 2 blood cancer win19
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
DoTakeda approval ushers in new wave of sleep drugs23
DoTakeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful3
DoTakeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval3
DoTakeda nets first-in-class advantage on narcolepsy drug's FDA go-ahead3
DoTakeda's first-in-class narcolepsy drug claims FDA approval5
DoTAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer1
DoTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::U.S. FDA APPROVES TAKEDA ORZEYFUL (OVEPOREXTON)6
30.07.Keros to receive $20 million milestone from Takeda partnership4
30.07.Keros Therapeutics, Inc.: Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda201LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...
► Artikel lesen
30.07.Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one25
30.07.Takeda Pharmaceutical Q1 Net Profit Slips From Higher Costs; Reaffirms FY26 Outlook384TOKYO (dpa-AFX) - On Thursday, Takeda Pharmaceutical Company Ltd. (TAK) reported decline in first quarter profit, dented by higher costs, despite higher revenues. Further, the company reiterated...
► Artikel lesen
30.07.Takeda Q1 FY2026 slides: three launches ahead as revenue dips17
30.07.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer4
30.07.TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::FIRST QUARTER RESULTS12
30.07.Takeda Pharmaceutical reports Q1 results20
23.07.Takeda gets first OK for orexin narcolepsy drug, in China11
22.07.Takeda's zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies6
20.07.Novartis and Takeda drugs gain rare blood cancer routine use on NHS22
17.07.Takeda reports zasocitinib psoriasis trial results at AAD meeting15
Weiter >>
163 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1